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Objective: Optimal management of renal artery stenosis (RAS) remains unclear. Recent randomized controlled trials have
shown no clear beneﬁt with percutaneous transluminal angioplasty with or without stenting (PTRA/S) over medical
management. We hypothesize that interventions for RAS are decreasing nationally.
Methods: The Nationwide Inpatient Sample, 1988-2009, was used to identify patients with a diagnosis of renal artery
atherosclerosis undergoing open surgical repair (bypass or endarterectomy) or PTRA/S. The rate of interventions, in-
hospital death, and perioperative outcomes were analyzed over time. Additionally, we used individual state inpatient
and ambulatory databases to better understand the inﬂuence of outpatient procedures on current volume and trends.
Results: We identiﬁed 308,549 PTRA/S and 33,147 open surgical repairs. PTRA/S increased from 1.9/100K adults in
1988 to 13.7 in 2006 followed by a decrease to 6.7 in 2009. Open surgical repair steadily decreased from 1.3/100K
adults in 1988 to 0.3 in 2009. In 2009, PTRA/S procedures (6.4/100K adults) greatly outnumbered procedures done
by open repair alone (0.1/100K), combined open renal and aortic repair (0.2/100K), and combined PTRA/S and
endovascular aneurysm repair (0.3/100K). From 2005 to 2009 33,953 patients underwent PTRA/S in the states of New
Jersey Maryland, Florida, and California combined. The total number of PTRA/S performed in the outpatient setting
remained stable from 2005 (3.8/100K) to 2009 (3.7/100K), whereas the total number of inpatient procedures mirrored
the national trend, declining from 2006 (7.9/100K) to 2009 (4.2/100K). PTRA/S had lower in-hospital mortality
(0.9% vs 4.1%; P < .001) compared with open repair. PTRA/S patients were more likely to be discharged home (86.2% vs
76.3%; P < .001) and had a shorter length of stay (4.4 vs 12.3 days; P < .001). Mortality was higher after combined open
renal and open aortic surgery compared to open repair alone (6.5% vs 4.1%; P < .001). Mortality was similar for combined
PTRA/S and endovascular aneurysm repair compared with PTRA/S alone (1.2% vs 0.9%; P [ .04).
Conclusions: The performance of PTRA/S procedures for the management of RAS has decreased signiﬁcantly after
2006. An increasing proportion of these procedures are performed in the outpatient setting. PTRA/S remains the
dominant revascularization procedure for RAS with lower in-hospital mortality and morbidity than surgery. (J Vasc
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Inclusion criteria varied for each study but included criteria
such as diastolic blood pressure, creatinine clearance, and
the percentage of renal artery lumen diameter reduction.
Outcome variables in these studies included mortality,
blood pressure control, required dosage of antihypertensive
medications, renal function, and procedural complications.
The data from these trials showed that there was no
clear beneﬁt for interventional treatments over medical
management.
Regardless, the number of renal artery interventions
had increased after the publication of these trials. National
inpatient data have shown a 173% increase in catheter-
based procedures from 1988 to 2001.6 The rate of inpa-
tient and outpatient percutaneous renal artery intervention
among Medicare beneﬁciaries increased 2.4-fold from
1996 to 2000.7 With the initial RCTs on interventional
treatment vs medical management of RAS published over
10 years ago and the continuing lack of evidence regarding
the optimal treatment for RAS, we wondered whether RAS
treatment has plateaued, declined, or continued to rise.
The purpose of this study was to evaluate national
trends in intervention for RAS using PTRA/S or open
surgery with and without aortic surgery. RAS encompasses
both renal atherosclerosis and ﬁbromuscular dysplasia, and
treatment of these is generally considered distinct, so1331
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performed.
METHODS
Databases. The Healthcare Cost and Utilization
Project is a family of health care databases including the
Nationwide Inpatient Sample (NIS) and State Inpatient
and Ambulatory Databases. The NIS is a 20% all-payer
sample of hospital stays and contains sampling weights
to allow for calculation of total population estimates. NIS
data are collected from hospital discharge abstracts, which
include information about all procedures performed during
a given hospital admission as well as patient characteristics,
comorbidities, in-hospital mortality, and length of stay.
The NIS currently consists of over 8 million annual
hospitalizations from 1050 hospitals in 44 states, repre-
senting approximately 95% of all hospitalizations. It is the
largest all-payer inpatient care database in the United
States.8
Many endovascular procedures have shifted to the
outpatient surgery setting and data regarding outpatient
procedures are not available in the NIS. However, New
Jersey, Maryland, Florida, and California are a few states
that make these data available in both their State Inpatient
Database and their State Ambulatory Surgery Database.
These databases represent a 100% sample of hospital
discharges and ambulatory procedures, respectively, within
each state. We analyzed the inpatient and ambulatory
surgery data in these states, years 2005 to 2009, to deter-
mine the extent to which the trends seen nationally are
simply a reﬂection of the changes in utilization of outpa-
tient care for RAS patients.
Data retrievaleNIS. Patients were selected in the NIS,
years 1988 to 2009, using diagnosis and procedure codes
from the International Classiﬁcation of Diseases, 9th Revi-
sion (ICD-9). Two groups of patients were studied: (1)
those with a diagnosis of renal atherosclerosis and (2) those
with a diagnosis of ﬁbromuscular dysplasia (FMD).
For renal atherosclerosis, patients were required to
have a primary diagnosis code for renal artery atheroscle-
rosis (440.1) or renovascular hypertension (405.01,
405.11, 405.91) combined with a procedural code for
open renal artery revascularization [endarterectomy
(38.16), resection of vessel with anastomosis (38.36),
resection of vessel with replacement (38.46), aortorenal
bypass (39.24), and reimplantation of renal artery
(39.55)] or angioplasty with or without stenting (PTRA/S)
[angioplasty or atherectomy of other noncoronary vessels
(39.50), other repair of vessel (39.59), or insertion of
nondrug-eluting peripheral vessel stent (39.90)]. Patients
with a concomitant diagnosis code for mesenteric ischemia
(55.70, 55.71) or vascular trauma (902.xx) were excluded.
Patients with a concomitant code for renovascular
hypertension and FMD were excluded from the renal
atherosclerosis group and instead classiﬁed in the FMD
group.
For FMD, patients were required to have a primary
diagnosis code for ﬁbromuscular dysplasia of the renalartery (447.3) combined with a procedural code for open
renal artery revascularization or PTRA/S. Patients with
a concomitant diagnosis code for mesenteric ischemia,
carotid stenosis (433.10, 433.11, 433.31), or vascular
trauma were excluded.
We also investigated combined procedures such as
open renal artery repair with aortic surgery and PTRA/S
with endovascular aneurysm repair (EVAR). Aortic surgery
procedure codes included endarterectomy (38.14), resec-
tion of vessel with anastomosis (38.34), resection of vessel
with replacement (38.44, 38.45), shunt or vascular bypass
(39.25), and other abdominal bypass (39.26). The EVAR
procedure code was 39.71. The adult population of the
United States for each year was determined from U.S.
Census Bureau data.9
Data retrievalestate databases. The inpatient and
ambulatory databases of the states of New Jersey, Califor-
nia, Maryland, and Florida were examined. Patients were
identiﬁed using ICD-9 diagnosis codes for renal artery
atherosclerosis, renovascular hypertension, and FMD. With
the exception of the state ambulatory databases of
California and Maryland, ICD-9 procedure codes were
used to identify all patients undergoing open renal artery
revascularization or PTRA/S. In the state ambulatory
databases of California and Maryland, current procedural
terminology codes were used to identify open renal artery
revascularization procedures (35341, 35536, 35636,
35560, and 35631) and PTRA/S (37205, 37207, 35450,
35471, 35480, and 35490).
Physician specialty determination. For PTRA/S, we
were interested in volume trends with the following
specialties: vascular surgeons (VS), interventional cardiol-
ogists (IC), and interventional radiologists (IR). NIS
provides unique physician identiﬁers per state that allows
tracking of procedures performed by that physician during
that speciﬁc year. Of the available states, 27 provided two
unique physician identiﬁers, of them 22 states speciﬁcally
stated which identiﬁer correlated with the primary proce-
dure performed. For the remaining ﬁve states, the identi-
ﬁers were only used when both were identical to make
sure that it involved the physician that performed the
primary procedure (the identiﬁers were identical in 75%
of cases). We composed a list of specialty-speciﬁc proce-
dures that we used to identify the specialty of each physi-
cian, which is included in the Supplementary Table,
online only. Similar approaches have been previously
reported.10-12 Subsequently, we created a hierarchical
model: each physician that performed >10 interventional
cardiac procedures was labeled an IC; physicians with >10
interventional radiology procedures were identiﬁed as IR;
the remaining physicians that performed 75% to 100%
vascular surgery procedures (of vascular and general
surgery codes combined) and >10 in number were clas-
siﬁed as VS. As these identiﬁers became available from
2001 onward, specialty-related analyses were restricted to
that period.
Outcomes. Our primary outcome was procedure utili-
zation over time. Secondary outcomes included in-hospital
Table I. Baseline characteristics of patients diagnosed with RAS or FMD undergoing PTRA/S or OR from 1988 to
2008
RAS FMD
PTRA/S OR P PTRA/S OR P
No. 308,549 33,147 6706 595
Age (mean 6 SD) 70.8 6 10.4 66.8 6 9.9 <.001 58.8 6 15.4 48.7 6 12.8 <.001
Female 56.2 47.3 <.001 88.9 83.6 <.001
Hypertension 74.8 54.9 <.001 78.2 36.7 <.001
PVD 67.9 79.2 <.001 29.5 38.5 <.001
COPD 16.2 21.8 <.001 7.2 9.9 .02
Prior MI 8.2 6.5 <.001 2.9 0.7 <.01
CHF 14.1 12.4 <.001 3.6 1.7 .01
Valvular disease 8.1 4.7 <.001 5.6 4 .11
Diabetes w/o comp 22.0 10.1 <.001 8.0 5.2 .02
Diabetes w/comp 4.8 2.0 <.001 0.7 0.0 .04
Chronic renal disease 8.8 3.0 <.001 2.6 0.0 <.001
Obesity 3.2 1.6 <.001 3.3 0.0 <.001
CHF, Congestive heart failure; COPD, chronic obstructive pulmonary disease; FMD, ﬁbromuscular dysplasia; MI, myocardial infarction; OR, open repair;
PTRA/S, percutaneous transluminal angioplasty with or without stenting; PVD, peripheral vascular disease; RAS, renal artery stenosis.
Values are in % unless otherwise indicated.
Fig 1. Annual number of inpatient procedures per 100K adults for
treatment of renal artery atherosclerosis from 1988 to 2009:
percutaneous transluminal angioplasty with or without stenting
(PTRA/S) compared with open repair.
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(997.02), cardiac complications (997.1), respiratory
complications (997.3), digestive complications (997.4),
genitourinary complications (997.5), vascular (997.71,
997.72, 997.79), peripheral vascular (997.2), wound
disruption (998.3), postoperative infection (998.5),
and hemorrhage/hematoma (998.11, 998.12)], length of
stay, and discharge disposition. We excluded patients with
combined procedures when analyzing outcomes after open
renal artery repair alone and PTRA/S alone.
Statistical analysis. Comparisons between cohorts
were done using the t-test for parametric continuous
data, and the Pearson c2 test for categorical and numeric
data. Continuous data are presented as mean 6 standard
deviation. Groups were stratiﬁed by diagnosis (renal
atherosclerosis vs FMD) and by procedural method
(open surgical repair vs PTRA/S). Queries were performed
using SAS 9.1 statistical software (SAS Institute, Cary,
NC). Statistical analyses were performed using PASW
18.0 (SPSS Inc, Chicago, Ill). Population estimates are
calculated by applying the sampling weight for each
observation. Statistical signiﬁcance was assigned at P < .05.
RESULTS
Patient characteristics. From 1988 to 2009, there
were 308,549 PTRA/S and 33,147 open surgical repairs
for patients with renal atherosclerosis and 6706 PTRA/S
and 595 open surgical repairs for patients with FMD.
The mean age was higher for patients receiving PTRA/S
compared with open repair for both renal atherosclerosis
(70.8 vs 66.8; P < .001) and FMD (58.8 vs 48.7; P <
.001) (Table I). Patients undergoing intervention for
FMD were younger than those undergoing intervention
for renal atherosclerosis (mean age, 59.4 vs 70.9; P <
.001), and FMD patients were more likely to be female
(87.0% vs 58.0%; P < .001).Renal artery atherosclerosis. Over the study period,
there were consistently more PTRA/S repairs in patients
with a diagnosis of renal atherosclerosis. PTRA/S interven-
tions increased substantially from 1988 to 2006 (1.9 to
13.7 procedures per 100K adults), followed by a marked
decrease from 2006 to 2009 (13.7 to 6.7 procedures per
100K adults), whereas the number of open repairs gradu-
ally decreased throughout the study period (1.3 to 0.3
procedures per 100K adults) (Fig 1). Compared with
open repair, patients undergoing PTRA/S had higher
rates of comorbidities except for peripheral vascular disease
and chronic obstructive pulmonary disease (Table I). The
mean age for PTRA/S intervention increased from
62.9 years in 1988 to 71.8 years in 2009 for patients with
renal atherosclerosis (P < .001) (Fig 2). No signiﬁcant
trend was seen for the mean age of open treatment of renal
atherosclerosis.
From 2005 to 2009, 20,759 patients in the state
inpatient databases (of New Jersey, Maryland, Florida, and
Fig 2. Change in mean age of patients undergoing inpatient
percutaneous transluminal angioplasty with or without stenting
(PTRA/S) or open renal artery revascularization for a diagnosis of
renal artery atherosclerosis from 1988 to 2009.
Fig 3. Annual number of percutaneous transluminal angioplasty
with or without stenting (PTRA/S) procedures per 100K adults
performed in New Jersey, Maryland, Florida, and California from
2005 to 2009 in patients with a diagnosis of renal atherosclerosis.
Table II. Perioperative complications and LOS after
PTRA/S and OR for patients with a diagnosis of RAS
PTRA/S OR P
Mortality 0.9 4.1 <.001
Discharged home 86.2 76.3 <.001
LOS, mean (SD) 4.4 (6.3) 12.3 (11.4) <.001
Stroke 0.2 0.7 <.001
Cardiac 0.3 6.1 <.001
Respiratory 0.3 6.1 <.001
Digestive 0.2 3.9 <.001
Urinary 0.7 4.3 <.001
Vascular 0.1 0.4 .87
Peripheral vascular 0.9 1.5 <.001
Wound disruption 0.1 0.8 <.001
Postoperative infection 0.2 1.6 <.001
Hemorrhage/hematoma 5.5 5.5 1.00
LOS, Length of stay; OR, open repair; PTRA/S, percutaneous transluminal
angioplasty with or without stenting; RAS, renal artery stenosis; SD, stan-
dard deviation.
Data presented as percentage unless otherwise indicated.
Fig 4. Annual number of procedures per 100K adults for
treatment of renal ﬁbromuscular dysplasia from 1988 to 2009;
percutaneous transluminal angioplasty with or without stenting
(PTRA/S) compared with open repair.
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surgery databases underwent PTRA/S for a diagnosis of
renal artery atherosclerosis. The number of PTRA/S per-
formed in the outpatient setting remained stable from
2005 (3.8/100K) to 2009 (3.7/100K), whereas the total
number of inpatient procedures declined from 2006 (7.9/
100K) to 2009 (4.2/100K) (Fig 3). The percentage of
outpatient procedures increased from 36% in 2005 to 47%
in 2009. There was no variability between states, as all
four states showed a decrease in total interventions
after 2006.
PTRA/S had lower overall in-hospital mortality
compared with open repair (0.9% vs 4.1%; P < .001)
(Table II). There was no signiﬁcant change in the year-to-
year in-hospital mortality trend from 1988 to 2009. The
proportion of patients discharged home was higher (86.2%
vs 76.3%; P < .001), and the length of stay was shorter
(4.4 vs 12.3 days; P < .001) after PTRA/S. PTRA/S had
fewer postoperative complications compared with open
repair in all categories except for hemorrhage andhematoma.
Renal ﬁbromuscular dysplasia. The change in the
rate of treatment for patients with FMD was similar to
that seen for patients with renal atherosclerosis. The
number of PTRA/S interventions increased from 1994
to 2006 (0.1-0.3 procedures per 100K adults) and
decreased from 2006 to 2009 (0.3-0.1 procedures per
100K adults) (Fig 4). Although the number of open
repairs ﬂuctuated over the study period, it consistently
remained lower than PTRA/S interventions per year.
Similar to patients with renal atherosclerosis, patients
undergoing PTRA/S had higher rates of comorbidities
except for peripheral vascular disease and chronic
obstructive pulmonary disease (Table I).
From 2005 to 2009, 357 patients in the state inpatient
databases (of New Jersey, Maryland, Florida, and Califor-
nia) and 422 patients in the state ambulatory surgery data-
bases underwent PTRA/S for a diagnosis of FMD. The
number of PTRA/S performed in the outpatient setting
increased from 2005 (0.12/100K) to 2007 (0.14/
100K) and declined from 2007 to 2009 (0.11/100K).
The trend in inpatient procedures mirrored the trend in
outpatient procedures, increasing from 2005 (0.11/
100K) to 2007 (0.12/100K) and declining from 2007to 2009 (0.07/100K). There was no variability between
states, as all four states showed a decrease in total interven-
tions after 2007.
In-hospital mortality was signiﬁcantly lower after
PTRA/S compared with open repair (1.6% vs 7.8%; P <
.001) (Table III). The proportion of patients discharged
Table III. Perioperative complications and LOS after
PTRA/S and OR for patients with a diagnosis of renal
FMD
PTRA/S OR P
Mortality 1.6 7.8 <.001
Discharge home 95.8 92.6 <.001
LOS, mean (SD) 2.8 (4.0) 7.9 (5.6) <.001
Stroke 2.3 0 .30
Cardiac 1.4 2.7 .06
Respiratory 0.8 12.5 <.001
Digestive 0.2 23.5 <.001
Urinary 1.2 7.7 <.001
Vascular 1.1 0 .21
Peripheral vascular 1.3 9 .11
Wound disruption 0.9 4.8 <.01
Postoperative infection 0 0 1.00
Hemorrhage/hematoma 5.8 5.2 .56
FMD, Fibromuscular dysplasia; LOS, length of stay; OR, open repair;
PTRA/S, percutaneous transluminal angioplasty with or without stenting;
SD, standard deviation.
Values are in %, unless otherwise indicated.
Fig 5. Annual number of inpatient procedures per 100K adults
for treatment of renal atherosclerosis from 1988 to 2009 by
percutaneous transluminal angioplasty with or without stenting
(PTRA/S) alone, open repair alone, open repair combined with
open aortic surgery, and PTRA/S combined with endovascular
aneurysm repair (EVAR) of the aorta.
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stay was shorter (2.8 vs 7.9; P < .001) after PTRA/S.
PTRA/S resulted in signiﬁcantly lower complication rates
of respiratory (0.8% vs 12.5%; P < .001), digestive (0.2%
vs 23.5%; P < .001), urinary (1.2% vs 7.7%; P < .001),
and wound disruption (0.9% vs 4.8%; P < .05).
Combined procedures. From 1988 to 2009, PTRA/S
was the predominant procedure for treatment of renal
artery atherosclerosis in the United States (Fig 5). In this
outcome analysis, patients with combined open aortic and
renal artery procedures and combined endovascular aortic
and renal artery procedures were excluded from the cate-
gories of open renal artery repair alone and PTRA/S alone,
respectively. PTRA/S alone greatly outnumbered the
procedures done by open repair alone, combined open
renal and open aortic surgery, and combined PTRA/S and
EVAR. Combined open renal and open aortic surgery
procedures outnumbered that of open repair alone
throughout the study period. Procedures done by
combined open renal and open aortic surgery decreased
with a trend similar to procedures done by open repair
alone.
The frequency of PTRA/S þ EVAR continued to
increase steadily after 2000, reaching a plateau between
2006 and 2009 at 0.3 procedures per 100K adults.
PTRA/S þ EVAR surpassed both the number of proce-
dures done by open repair alone and procedures done by
combined open renal and open aortic surgery in 2006.
Overall mortality was higher after combined open renal
and open aortic surgery compared with open renal repair
alone (6.5% vs 4.1%; P < .001) (Table IV). The proportion
of patients discharged home was signiﬁcantly higher after
open repair alone (76.3% vs 69.2%; P < .001). However,
length of stay was similar. There were signiﬁcantly
more cardiac, respiratory, and urinary complications after
combined open renal and open aortic surgery.Although discharge home was less frequent after
PTRA/S þ EVAR compared with those undergoing
PTRA/S alone (77.1% vs 86.2%; P < .001), overall
mortality remained similar (1.2% vs 0.9%; P ¼ .04).
PTRA/S þ EVAR had signiﬁcantly higher complications
compared with patients undergoing PTRA/S alone.
Physician specialty analysis. In 2001, IC performed
the majority (70.8%) of all PTRA/S in patients with renal
artery atherosclerosis, followed by IR (16.7%), and VS
(12.5%). In 2009, IC continued to perform the majority
of interventions (71.3%), followed by VS (21.1%) and IR
(7.6%). IC performed an increasing number of PTRA/S
between the years 2001 (2.8/100K) and 2006 (5.1/
100K) followed by a steep decrease to 2.4/100K in
2009 (Fig 6). Similarly, VS performed an increasing
number of PTRA/S between 2001 (0.5/100K) and 2006
(1.4/100K) followed by a decline to 0.7/100K in 2009.
IR experienced a steady decrease in procedures from 2001
(0.7/100K) to 2009 (0.3/100K).
DISCUSSION
After a rapid increase in the number of PTRA/S proce-
dures performed for the management of RAS between
1988 and 2006, a signiﬁcant decrease in the number of
PTRA/S procedures followed. This decrease was only
seen in the inpatient setting, as the number of outpatient
procedures remained constant. The management of FMD
was similar compared with the intervention trend for renal
atherosclerosis but on a smaller scale. The increase in
mean age for patients undergoing PTRA/S from 1988 to
2009 may reﬂect an increase in the use of medical manage-
ment early in renal atherosclerotic disease prior to interven-
tion. The number of open repair procedures with or
without open aortic surgery repair consistently decreased
throughout the study period, reﬂecting a shift toward less
invasive procedures. The trend toward minimally invasive
procedures is further supported by an increase in the
number of combined PTRA/S and EVAR procedures
beginning in 2000.
The rise in the number of PTRA/S procedures per-
formed prior to 2006 has previously been appreciated.
Table IV. Perioperative complications and LOS after OR alone, OR þ AS, PTRA/S alone, and PTRA/S þ EVAR for
patients with a diagnosis of RAS
OR OR þ AS P PTRA/S PTRA/S þ EVAR P
Mortality 4.1 6.5 <.001 0.9 1.2 .04
Discharge home 76.3 69.2 <.001 86.2 77.1 <.001
LOS, mean (SD) 12.3 (11.4) 12.7 (45.1) .33 4.4 (6.3) 4.2 (5.3) <.001
Stroke 0.8 0.6 .40 0.2 0.3 .08
Cardiac 5.5 6.8 <.001 0.8 2.1 <.001
Respiratory 6.2 7.9 <.001 0.3 0.3 .76
Digestive 3.9 4.4 .05 0.2 0.9 <.001
Urinary 4.3 5.7 <.001 0.7 1.5 <.001
Vascular 0.1 0.1 .58 0.1 0.7 <.001
Peripheral vascular 1.6 1.3 .04 0.9 1.0 .56
Wound disruption 0.5 0.8 <.01 0.1 0.4 <.001
Postop infection 1.6 1.3 .07 0.2 0.4 <.01
Hemorrhage 5.5 4.0 <.001 5.5 4.5 <.01
AS, Aortic surgery; EVAR, endovascular aneurysm repair; LOS, length of stay; OR, open repair; PTRA/S, percutaneous transluminal angioplasty with or
without stenting; RAS, renal artery stenosis; SD, standard deviation.
Values are in %, unless otherwise indicated.
Fig 6. Percutaneous transluminal angioplasty with or without
stenting (PTRA/S) procedures per 100K adults performed by
vascular surgeons, interventional cardiologists, and interventional
radiologists from 2001 to 2009.
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(1996, 1998, 2000)7 have previously shown a similar rapid
increase in percutaneous renal artery interventions prior to
2001, but our study now reveals a reversal of this trend
with a decline in percutaneous renal artery therapy after
2006. This decrease in the number of interventional treat-
ments for RAS may be explained by a lack of demonstrated
beneﬁt of procedural intervention in recent RCTs.
Three small RCTs, all with less than 136 total patients,
were published between 1998 and 2000, comparing PTRA
without stenting and medial management.1-3 In 1998,
the Essai Multicentrique Medicaments vs Angioplastie
(EMMA) study found that patients treated with angio-
plasty experienced more complications, but had better
blood pressure control with half as many antihypertensive
agents. However, blood pressure response after 6 months
and renal function was not different between the treatment
groups.1 Similarly, the Scottish and Newcastle Renal Artery
Stenosis Collaborative Group (SNRASCG) study found no
difference in blood pressure or renal function between
angioplasty and medical management.3 In 2000, the
Dutch Renal Artery Stenosis Intervention Cooperative
(DRASTIC) trial reported no blood pressure or renalfunction difference between the two treatment groups using
intention-to-treat analysis but found the average daily drug
dose was signiﬁcantly lower in the angioplasty group.2 These
trials were limited by factors such as small sample size,
infrequent use of stenting, inclusion of patients with only
mild-to-moderate RAS (>50%-60%), and high crossover
rates from medical to revascularization treatments.
The demonstration of success with renal stenting13 over
angioplasty alone in 1999 spearheaded a number of trials to
compare renal angioplasty with stenting and medical
management. In 2009, the STAR trial, which included
140 patients with RAS >50%, creatinine clearance <80
mL/min, and a controlled blood pressure <140/90 mm
Hg, concluded that renal stenting had no beneﬁt over
medical therapy.5 However, this study has been criticized
because a large number of patients with mild-to-moderate
renal disease and controlled hypertension were included,
which under normal clinical circumstances, would not
have been treated by renal artery stenting. Additionally,
the criterion of RAS of >50% may include patients who
do not have hemodynamically signiﬁcant stenoses.
In 2009, the Angioplasty and Stenting for Renal Artery
Lesions (ASTRAL) trial, enrolling a total of 806 patients,
found no difference in mortality, systolic and diastolic
blood pressure, vascular events, renal function, or adverse
renal events between the two treatment options.4
However, the ASTRAL trial has also been under scrutiny
and criticism; 41% of patients included in the trial
had <70% stenosis, patients who the treating clinician
believed would beneﬁt from renal stenting were excluded,
and there was no deﬁned treatment regimen for medical
therapy.14 The results from three other large RCTs have
yet to be published; the RAVE (Renal Atherosclerotic
Revascularization Evaluation) trial, the RADAR (a ran-
domized multicenter prospective study comparing best
medical treatment versus best medical treatment plus renal
artery stenting in patients with hemodynamically relevant
atherosclerotic renal artery stenosis) study, and the
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rotic Lesions) trial.15 Of these trials, the CORAL trial is
unique in that it is the largest andmost scientiﬁcally rigorous
of all the current trials.16 The weaknesses and criticisms for
RCTs evaluating management of RAS are reﬂected in the
2005 American College of Cardiology/American Heart
Association (ACC/AHA)’s lack of deﬁnitive treatment
guidelines for RAS treatment and the 2006 AHRQ analysis
conclusion for a need of higher-quality evidence studies for
the treatment of RAS.17,18 These management guidelines
combined with the mounting lack of evidence from RCTs
to support PTRA/S likely contributed to the sharp drop
in the number of PTRA/S starting in 2006, well before
the reported results from the ASTRAL or STAR trials.
The number of open repairs, with and without aortic
surgery, steadily declined throughout our study, reﬂecting
the movement toward less invasive therapies. A retrospec-
tive study, evaluating renal angioplasty, stent placement,
and bypass grafting, concluded that these procedures
were all equally efﬁcacious for control of renovascular
hypertension, but the initial treatment cost for bypass graft-
ing was signiﬁcantly higher than that for angioplasty and
stenting.19 However, the ACC/AHA guidelines do
recommend the use of surgical intervention in certain clin-
ical situations. This includes patients with FMD exhibiting
macroaneurysms or complex disease that extends into
the segmental arteries, patients with atherosclerotic RAS
exhibiting multiple small renal arteries or early primary
branching of the main renal artery, and patients with
atherosclerotic RAS in combination with pararenal aortic
reconstruction (in the treatment of aortic aneurysms or
severe aortoiliac occlusive disease).17 Despite the various
situations where open revascularization with or without
open aortic surgery has been indicated, our data have
shown that the majority of interventions for RAS have
shifted away from open repair.
Because of the growing popularity in EVAR proce-
dures, we hypothesized that there would be a growing
movement toward combined PTRA/S and EVAR proce-
dures (PTRA/S þ EVAR) for patients with both renal
artery and aortic disease. The ﬁrst two EVAR stent grafts
to be approved by the U.S. Food and Drug Administration
occurred in September 1999 and the ICD-9 code for
EVAR was subsequently introduced in 2000. Thereafter,
the number of combined PTRA/S þ EVAR procedures
has continued to rise. Our results demonstrate that
PTRA/S þ EVAR procedures resulted in higher postoper-
ative complications compared with PTRA/S alone, as ex-
pected due to the increased procedural complexity and
disease severity for patients undergoing combined proce-
dures. We expect that the number of combined minimally
invasive procedures will continue to increase in the future.
IC, IR, andVShave all been involvedwith the procedural
treatment of RAS. We found a decrease in the number of
PTRA/S procedure performed for all three specialities
after 2006, reﬂecting a universal movement away from
PTRA/S. However, it is clear that IC continue to perform
the largest number of PTRA/S for RAS.The limitations to this study are inherent to studies
using administrative data, such as the accuracy of hospital
coding of comorbidities and complications. Alterations in
coding methods in the NIS are therefore a potential for
error, and in some instances, makes it difﬁcult to differen-
tiate perioperative complications from pre-existing condi-
tions. Diagnosis codes may have been selected by clinical
or ﬁnancial importance, thereby explaining the fact that
a lower proportion than expected of patients, particularly
patients with open surgery intervention, had a diagnosis
code for hypertension. There was no randomization
between treatment options in this study, and the selection
of treatment method was at the treating physician’s discre-
tion. However, our primary objective was to document
changes in utilization of PTRA/S and open surgery for
RAS. In this regard, the NIS is an ideal tool. We had access
to outpatient data from four states that may not accurately
reﬂect the entirety of the United States. However, the
results in these diverse states were similar and the inpatient
utilization represented by the NIS was corroborated by
inpatient data from these states.
The NIS allows for evaluation of a large patient sample.
Therefore, we are able to draw strong conclusions in the
trend of RAS treatment in the United States. We ultimately
conclude that interventions for RAS have declined since
2006, likely because in part of a lack of demonstrated
beneﬁt in RCTs. Analysis of the State Inpatient and Ambu-
latory Surgery databases have shown that this decrease in
PTRA/S seen nationally is only found in the inpatient
setting while outpatient procedures have remained stable.
Nevertheless, as interventions have decreased nationally,
PTRA/S remains the dominant procedural option
compared with open interventions because of its lower
rate of mortality and morbidity.AUTHOR CONTRIBUTIONS
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Supplementary Table (online only). International
Classiﬁcation of Diseases, 9th Revision (ICD-9)
procedure codes used to identify the physician specialty of
vascular surgeons, general surgeons, interventional
cardiologists, and interventional radiologists
Vascular surgeon
38.12 Carotid endarterectomy














33.26 Closed lung biopsy
39.1 Transjugular intrahepatic portosystemic shunt
50.11 Closed liver biopsy
55.03-04 Percutaneous nephrostomy
78.49, 81.65 Percutaneous vertebroplasty
99.25 Chemoembolization
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